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Abstract One of the main problems of anti-cancer therapy
is an insufficient differentiation between normal and
malignant cells by the known anti-proliferant agents. The
antibody-directed enzyme prodrug therapy is a promising
approach for a selective treatment of cancer, in which a
non-toxic prodrug is enzymatically converted into a highly
cytotoxic drug at the surface of malignant cells by a
targeted antibody–enzyme conjugate. The transformations
and the stability of a very promising novel prodrug and its
corresponding cytotoxic derivative were now investigated
in detail by high-performance liquid chromatography
(HPLC)–mass spectrometry (MS). In order to determine
the time-dependent DNA alkylation efficiency and the
sequence selectivity of the novel compounds, DNA binding
studies using direct electrospray–Fourier transform ion
cyclotron resonance–MS (ESI–FTICR–MS) have been
performed. These measurements were accompanied by
HPLC analyses followed by MS of the separated species
to confirm the results of the direct ESI–FTICR–MS
measurements. The sites of DNA alkylation could be
identified unambiguously by the mass spectrometric frag-
mentation pattern of the alkylated oligodeoxynucleotides as
well as by the results of HPLC followed by MS. A
combination of all techniques applied led to a better
understanding of the mode of action of the new therapeutics
and might be used for an estimation of the cytotoxicity of
different prodrugs and drugs since the alkylation efficiency
correlates with the bioactivity of the compounds in cell
culture investigations.
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Abbreviations
A Adenine
ADEPT Antibody-directed enzyme prodrug
therapy
AuC Area under the curve
CID collision-induced dissociation
CSD capillary-skimmer dissociation
DNA Deoxyribonucleic acid
ESI–FTICR–MS electrospray–Fourier transform ion
cyclotron resonance–mass spectrometry
HPLC–MS high-pressure/performance liquid
chromatography–mass spectrometry
Introduction
Despite considerable efforts towards the development of
efficient and selective cancer therapies, most anti-cancer
agents applied so far in the clinic cause severe side effects
because their cytotoxic action is not limited to the tumour
cells. To minimise these side effects, current research focuses
on the development of targeted tumour therapies. In antibody-
directed enzyme prodrug therapy (ADEPT), relatively non-
toxic prodrugs are converted to their corresponding highly
cytotoxic drugs selectively in the tumour tissue by targeted
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drugs is thus limited mainly to the tumour site. For a
successful application of ADEPT, water-soluble and stable
prodrugs with low cytotoxicity that yield highly cytotoxic
drugs after enzymatic activation are needed [4]. Furthermore,
insights into the mode of action of the potential therapeutics
are highly desirable for a safe drug administration and a
sophisticated drug development.
Recently, we have prepared a series of novel glycosidic
prodrugs like the anti-methyl-seco-CBI-DMAI-galactoside 1,
which can be activated enzymatically by cleavage of the
sugar moiety using commercially available β-D-galactosidase
from Escherichia coli to give the corresponding seco-drug 2
(Fig. 1)[ 5, 6]. 2 was expected to cyclise rapidly under loss of
HCl to produce the active drug 3 which is an analogue of the
highly cytotoxic natural antibiotic CC-1065 (4)[ 7] and the
duocarmycins (e.g. duocarmycin SA (5)) [8].
Since 4 and 5 are supposed to exert their cytotoxic action
through alkylation of adenine in AT-rich minor grooves of
double-stranded DNA, drugs such as 3 are expected to
alkylate cellular DNA, and it can be assumed that the
sequence selectivity in the DNA alkylation correlates to the
biological activity [9-11]. By means of cell culture inves-
tigations using human bronchial carcinoma cells of line
A549, it was shown that prodrug 1 is 4,800 times less toxic
than its corresponding drug 3, which exhibits a high
cytotoxicity with an IC50 of 0.75 nM [5, 6].
Here, we describe investigations aimed at a better under-
standingofthemodeofactionofprodrugs suchas1.F i r s t ,t h e
stability of prodrug 1 and of the enzymatic activation of the
prodrug to give the corresponding seco-drug 2 using high-
performance liquid chromatography (HPLC)–mass spectrom-
etry (MS) was investigated. Furthermore, the transformations
of the seco-drug 2 to the drug 3 under cell culture conditions
and of the further transformations of the drug were studied
by means of HPLC–MS. Second, the time-dependent DNA
alkylation efficiency and the sequence selectivity of prodrug
1 and of its corresponding seco-drug 2 were investigated
using HPLC followed by MS as well as by means of direct
electrospray ionisation (ESI)–Fourier transform ion cyclotron
resonance (FTICR)–MS. A short communication of parts of
this work, namely the use of direct ESI–FTICR–MS for the
Fig. 1 Galactosidic prodrug 1 containing a detoxifying sugar moiety,
enzymatic activation of prodrug 1 to give seco-drug 2 followed by a
cyclisation of 2 to afford the active drug 3 as an analogue of the
natural products CC-1065 (4) and duocarmycin SA (5). Inactivation of
1, 2 or 3 by hydrolysis leads to 6 and 7, respectively
438 L.F. Tietze et al.investigation of the alkylation reaction, has recently been
published [12].
Experimental
Materials
Prodrug 1 and seco-drug 2 were synthesised according to
previously published procedures [5] and stock solutions in
dimethyl sulfoxide (DMSO) were prepared. UltraCulture®
(Lonza, Germany) supplemented with 2 mML -glutamine
from Gibco was used as cell culture medium. For the
investigation of the enzymatic activation of 1, β-D-
galactosidase from E. coli (E.C. 3.2.1.23, G 5635, activity
700 units (U) per milligramme protein at pH7.3 and 37°C,
1 U = conversion of 1µmol of substrate per minute, Sigma,
Germany) was added. The synthetic dsDNA oligomer 5′-d
(CGGTCAATTAGTCGC)-3′ (ON-1) ∙ 3′-d(GCCAGTTAAT
CAGCG)-5′ (ON-2) was purchased from IBA (Göttingen,
Germany) as aqueous solution (0.1 mM) of the respective
sodium salt.
Methods
Transformations of prodrug 1 and seco-drug 2 in cell
culture medium
Ten microlitres of a stock solution of 1 or 2 in DMSO
(48 mM) was mixed with 990 µL cell culture medium, and
the resulting reaction mixture was incubated at 37°C for
24 h. Samples were taken after 0.0, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0,
5.0, 6.0 and 24.0 h. For the investigation of the enzymatic
activation of 1, β-D-galactosidase (10 U mL
−1) was added
prior to the incubation and additional samples were taken
after 2.5 and 7 h. The samples without β-D-galactosidase
were directly investigated by HPLC–MS. The samples with
β-D-galactosidase were subjected to ultracentrifugation using
common polymerase chain reaction (PCR) filters
(UFC7PCR50, Millipore, Germany) to remove the enzyme;
the filter was washed with an equivalent amount of methanol,
and HPLC–MS of the combined eluents was performed.
High-performance liquid chromatography–mass
spectrometry
Chromatography was performed with an HPLC system
consisting of a Rheos 4000 solvent pump and an ERC-3415
degasser from Flux Instruments, an autosampler 851-AS
from Jasco and a diode array detector Surveyor PDA
operated at 200–800 nm from Thermo. As column, a
Synergi Max-RP C12 (150×2 mm, 4µm) from phenomenex
was used. Samples were eluted within 15 min with a flow
rate of 300 µL min
−1 by applying a gradient (0–15 min
30→100% B, 15–22 min 100% B, 22–23 min 100→30%
B, 23–29 min 30% B). Eluent A was water with 0.05%
formic acid from Roth. Eluent B was methanol from VWR
with 0.05% formic acid from Roth. Online ESI mass
spectrometry was performed in the positive mode with an
ion-trap mass spectrometer LCQ from Finnigan with
detection in the mass range of 100–2000m/z. The capillary
temperature was set to 220°C, the spray voltage to 4.5 kV
and the sheath gas flow to 80 (arbitrary units). For each
measurement, the area under the curve (AuC, reconstructed
ion chromatogram versus retention time) of all species
including an internal standard was determined and the
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Fig. 2 Transformation of the galactosidic prodrug 1 in the absence of β-D-galactosidase to give the hydroxylated derivative 6. AuC against time
and chromatograms after 0.0 h and 24.0 h of incubation
Investigation of the transformations of a novel anti-cancer agent 439respective relative area under the curve was calculated. The
measurements were performed in triplicate, and the median
relative area under the curve of each species was then
plotted versus time.
Investigation of the DNA alkylation of prodrug 1
and seco-drug 2
The reactions were carried out in aqueous solution with
0.1 mmol L
−1 dsDNA and prodrug 1 or seco-drug 2 in a 1:1
and 1:5 ratio. One microlitre of stock solution of 1 or 2 was
mixed with 100 µL of dsDNA in water, and the reaction
mixture was incubated at 25°C for 24 h. For direct
investigations of the reaction mixtures, samples were taken
at 0 and 24 h, diluted with an equivalent amount of
methanol and the resulting solution introduced directly into
the ion source of the ESI–FTICR mass spectrometer. For
comparison, the samples were separated using HPLC, the
sample fractions lyophilised, dissolved in a mixture of
water/methanol (1:1) and the resulting solutions introduced
into the ion source of the ESI–FTICR mass spectrometer.
Additionally, selected samples were heated to 95°C for 2 h
and then subjected to HPLC, lyophilisation and high-
resolution mass spectrometry.
0
10
20
30
40
50
60
70
80
90
100
0 5 10 15 20 25
time [h]
A
u
C
 
[
%
]
seco-drug 2
drug 3
hydroxylated drug 7
dimeric drug
50
100
10000
20000
time [min]
i
n
t
e
n
s
i
t
y
 
[
a
.
u
.
]
UV
total scan
MS
base peak
t = 0.0 h
50
100
5000
10000 2
3 7 UV
total scan
MS
base peak
t = 1.5 h
i
n
t
e
n
s
i
t
y
 
[
a
.
u
.
]
2
3 7
Fig. 4 Cyclisation of the seco-drug 2 to give the drug 3 followed by hydrolysis to give the hydroxylated species 7 and reaction to afford a dimeric
drug. AuC against time and chromatograms after 0.0 h and 1.5 h of incubation
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Fig. 3 Transformation of prodrug 1 in the presence of β-D-
galactosidase to the corresponding seco-drug 2 and rapid cyclisation
of 2 to the drug 3. Hydrolysis of 1 and 3 to the hydroxylated species 6
and 7, respectively, and formation of a dimeric drug. AuC against time
and chromatograms after 0.0 h and 1.5 h of incubation
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alkylated by the drug 3, w5 (ON-1) and a10-B10 (ON-1): fragments of
ON-1–A indicating alkylation at A-10 of ON-1
Investigation of the transformations of a novel anti-cancer agent 441Semi-preparative high-performance liquid chromatography
HPLC separations were performed with an Agilent 1200
with diode array detector from Agilent Technologies,a n
Aquapore OD-300 Column (220×4.6 mm, 7µm) from
Perkin Elmer and a Bondapak® C18 Column (300×
3.9 mm, particle size 10µm, pore size 125Å) from Waters.
Samples were eluted within 45 min with a flow rate of 1 mL
min
−1 (Aquapore OD-300) or 2 mL min
−1 (Bondapak® C18)
at 28°C by applying a two-stage gradient (0–2 min 5% B, 2–
22 min 5→20% B, 55–45 min 20→80% B, 45–50 min 80%
B, 50–60 min 80→5% B). Eluent A was 0.1 mol L
−1
triethylammonium acetate buffer (H2O, pH7.0). Eluent B
was 0.1 mol L
−1 triethylammonium acetate buffer (80%
acetonitrile and 20% water, pH 7.0).
High-resolution electrospray mass spectrometry
High-resolution mass spectrometry was performed using a
7-T FTICR–MS instrument (APEX IV, Bruker Daltonics,
Billerica, USA) equipped with an APOLLO electrospray ion
source and a syringe pump (74900 series, Cole-Parmer,
Vernon Hills, USA) with a flow rate of 2µL min
−1 for sample
injection. The ions generated in the negative ion mode were
accumulated in the hexapole region for 0.8 s and transferred
subsequently into the ion cyclotron resonance (ICR) cell. For
gentle desolvation, the drying gas temperature was set to
100°C and the capillary exit voltage to −100 V. Enh anced
fragmentation of alkylated oligonucleotides was achieved
by capillary-skimmer dissociation (CSD) with a capillary
exit voltage of −150 V. Collision-induced dissociation
(CID)–MS/MS measurements were carried out by fragmen-
tation of ions isolated in the ICR cell using argon as collision
gas.
Results and discussion
First, the stability of prodrug 1 in cell culture medium at
37°C was determined using HPLC–MS (Fig. 2, for mass
spectra, tables and chromatograms: see Supplementary
Material Figs. S1–S2 and Table S1). In the time period of
24 h, no cleavage of the sugar moiety in 1,i . e .n oa c t i v a t i o n
of 1 to give the corresponding highly cytotoxic derivatives 2
and 3, was observed. Instead, as was obvious from the
chromatograms and the respective mass spectra, nucleophilic
substitution of the chlorine atom in 1 by a hydroxyl group
occurred, transforming 1 into to the derivative 6.I nt h e
absence of β-D-galactosidase, 1 has a half-life of approxi-
mately 14±1 hours.
In the presence of β-D-galactosidase, prodrug 1 was
efficiently activated to the corresponding seco-drug 2 by
removal of the sugar moiety in 1 (Fig. 3, for additional
chromatograms and tables: see Supplementary Material Fig.
S3 and Table S2).
As was expected, 2 cyclised rapidly under loss of HCl to
give the highly reactive drug 3 directly after its generation
from the prodrug 1. More slowly, prodrug 1 and drug 3
were both hydrolysed to provide the hydroxylated species 6
and 7, respectively. Furthermore, in the absence of other
potential nucleophiles, drug 3 very slowly reacted to give a
dimeric species.
In order to investigate the kinetics of the cyclisation of
seco-drug 2 to the corresponding drug 3 in detail, the
transformations of 2 in cell culture medium at 37°C were
studied using the same method as described for the prodrug
1 (Fig. 4, for mass spectra, chromatograms and tables: see
Supplementary Material Figs. S4–S5 and Table S3).
As was already observed for the seco-drug 2 that is
generated from 1 in situ (Fig. 3), a pure sample of 2 cyclises
HO P P P P P P P P P P P P P P OH 5' 3'
C1 G2 G3 T4 C5 A7 A6 T8 T9 A10 G11 T12 C13 G14 C15
OH P P P P P P P P P P P P P P 5' 3'
G1 G3 A4 C5 A7 T6 A8 T9 T10 G11 A12 C13 G15
HO
C2 C14
A*
w5 (ON-1) a10–B10 (ON-1)
ON-2
ON-1*
Fig. 7 Fragmentation of the
alkylated oligonucleotide
ON-1* into A*, w5 (ON-1) and
a10-B10 (ON-1) [16]
442 L.F. Tietze et al.rapidly to give the corresponding drug 3 after its mixing
with cell culture medium (Fig. 4). 3 is then hydroxylated by
nucleophilic substitution and reacts to a dimeric derivative.
The identity of each compound was verified by ESI–MS
and ESI–MS/MS experiments. Thus, it was shown that the
dimeric species is formed by a reaction of the hydroxylated
drug 7 with the drug 3 (for MS and MS/MS spectra: see
Supplementary Material Fig. S5). A dimerisation of the drug
under physiological conditions is unlikely to occur due to
the presence of a multitude of nucleophiles with higher
reactivity in biological systems and the lower concentrations
used for a therapeutic application as compared to the
HPLC–MS studies. The deactivation of the drug 3 in the
time window observed is desirable for a clinical application
of prodrug 1 because a long lifetime of 3 might cause
undesirable side effects due to its leaking out of the tumour
site by means of diffusion.
In order to investigate the DNA alkylation efficiency of
prodrug 1 and seco-drug 2, both compounds were incubat-
ed with the synthetic double-stranded DNA oligomer 5′-d
(CGGTCAATTAGTCGC)-3′ (ON-1) ∙ 3′-d(GCCAGTTAAT
CAGCG)-5′ (ON-2) in aqueous solution [12].
After incubation of the dsDNA ON-1∙ON-2 with the
seco-drug 2 in a ratio of 1:1 for 24 h, a very efficient and
selective alkylation of the oligonucleotide ON-1 by the
intermediately formed drug 3 could be observed using
direct ESI–FTICR–MS measurements (Figs. 5 and 6, for
tables of the masses calculated and found: see Supplemen-
tary Material Tables S4–S6).
Whereas the reaction mixture after 0 h of incubation
shows only the signals of the seco-drug 2, the drug 3 and of
the two oligonucleotides ON-1 and ON-2 (Fig. 6a),
additional peaks of the covalent adduct ON-1*,t h e
depurinated oligonucleotide ON-1–A and the alkylated
nucleobase adenin A* could be observed after 24 h of
incubation (Fig. 6b).
Applying a CapExit voltage of −100 V, the alkylated
oligonucleotide ON-1* underwent a partial fragmentation
affording the depurinated oligonucleotide ON-1–A [13-15].
Increasing the CapExit voltage to −150 V induced a further
fragmentation of the depurinated oligonucleotide ON-1–A
to provide the secondary fragments w5 (ON-1) and a10-B10
(ON-1) by CSD (Fig. 6c).
1 The same fragmentation could
also be achieved by CID of ON-1–A in an MS/MS
experiment using argon as the collision gas (Fig. 6d, for
calculated and found masses: see Supplementary Material
Table S7). The fragmentation pattern clearly shows that the
alkylation took place selectively at A-10 of the single-
strand ON-1 of the double-stranded oligonucleotide, which
is situated at the 3′ end of an AT-rich region (Fig. 7). This
selectivity was also found for the natural products CC-1065
and duocarmycin SA [9-11].
The modification of the nucleobase weakens the N-
glycosidic bond, favouring a depurination of ON-1* under
participation of the neighbouring O-atom to afford the
primary fragments ON-1–A and A* under mild ionisation
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capillary exit voltage, the depurinated oligonucleotide
ON-1–A degrades via 1,2-elimination to give the secondary
fragments w5 (ON-1) and a10-B10 (ON-1) that are indica-
tive of the exact position of the alkylation reaction, namely
the nucleobase A-10 of ON-1 (Fig. 7)[ 13-15].
Based on the peak intensities of the corresponding
isotope peaks including all sodium adducts, the percentage
of alkylation per hour (A
t) was calculated considering an
incubation time of up to 6 h with measurements in
triplicate being performed every hour (for data, see
Supplementary Material Table S8). Calculations of the
alkylation rate using the deconvoluted spectra gave the
same results as were obtained using the corresponding
native spectra. According to Eq. 1, the alkylation rate was
determined to be approximately 10% per hour (Fig. 9).
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Fig. 12 Mass spectra of mixtures of the dsDNA ON-1∙ON-2 and
prodrug 1 in a ratio of a 1:1 and b 1:5 after incubation of the
respective reaction mixture for 24 h at 25°C; CapExit voltage −100 V.
ON-1*:ON-1 alkylated by prodrug 1; ON-2*:ON-2 alkylated by
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Fig. 13 Deconvoluted mass spectra of a mixture of the dsDNA ON-1∙ON-2 and prodrug 1 in a ratio of 1:5 after 24 h of incubation in water at 25
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Qt
Q0
Qt median ratio of the intensities of the corresponding
isotope peaks and sodium adducts of ON-1 to the
respective signals of ON-2 at the incubation time t
Q0 median ratio of the intensities of the corresponding
isotope peaks and sodium adducts of ON-1 to the
respective signals of ON-2 at the incubation time 0 h.
Compared to previous studies based on mass spectrom-
etry [16-21], this procedure allows the determination of the
alkylation efficiency and the alkylation position without
prior purification and enrichment of the products using
HPLC before the mass spectrometric investigations [12].
Furthermore, in comparison to other methods for the
analysis of DNA–drug complexes, such as NMR spectros-
copy [22, 23] and X-ray crystal structure analysis [24], as
well as PCR stop assay, DNAseI footprinting and poly-
acrylamide gel electrophoresis after thermally induced
strand cleavage [25-29], the procedure offers some conve-
nient advantages like a fast determination of alkylation
efficiencies and sequence selectivities with low sample
amounts and without prior sample manipulation.
To confirm the results obtained by direct ESI–HRMS
measurements, HPLC of the reaction mixtures followed by
ESI–HRMS of the eluted fractions was performed. Again,
the alkylation rate was approximately 10% per hour and the
reaction took place selectively at A-10 of ON-1. When the
reaction mixture was incubated for 24 h and heated up to
95°C for 2 h prior to the HPLC separation and ESI–HRMS
analyses of the eluates, cleavage of the alkylated oligonu-
cleotide ON-1* intothefragmentsw5 (ON-1) and d9 (ON-1)
occurred (Fig. 10, for tables of the masses calculated and
found: see Supplementary Material Tables S9). Thus, the
alkylation took place selectively at A-10 of ON-1; however,
a slightly different mechanism of fragmentation of the
alkylated oligonucleotide ON-1* in solution (Fig. 11)a s
compared to the fragmentation in the mass spectrometer
(Fig. 8) was observed.
In solution, the alkylated nucleobase A* is supposed to
be cleaved from the oligonucleotide under subsequent
attack of water to give the hemiacetal ON-1–A+H2O. This
hemiacetal isomerises to the corresponding aldehyde, which
HO P P P P P P P P P P P P P P OH 5' 3'
CGGT C A AT T A 10 GTCGC
OH P P P P P P P P P P P P P P 5' 3'
G G A C A7 T A T T G A C G
HO
C C
A*
w5 (ON-1) a10–B10 (ON-1)
ON-2
ON-1*
HO P P P P P P P P P P P P P P OH 5' 3'
C GGTC A AT T A 10 G TCG C
OH P P P P P P P P P P P P P P 5' 3'
G G A C A7 T A T T G A C G
HO
C C
A*
w8 (ON-2) a7–B7 (ON-2)
ON-2*
ON-1
Fig. 14 Fragmentation of the
alkylated oligonucleotide ON-1*
into A*, w5 (ON-1) and
a10-B10 (ON-1) indicative of the
alkylation at A-10 of ON-1 and
of the alkylated oligonucleotide
ON-2* into A*, w8 (ON-2) and
a7-B7 (ON-2) indicative of the
alkylation at A-7 of ON-2
(1)
446 L.F. Tietze et al.is prone to a 1,2-elimination of w5 (ON-1) followed by a
1,2-elimination of d9 (ON-1) [13-15].
Notably, the non-covalent interactions between the
unmodified DNA oligonucleotides (ON-1∙ON-2) as well
as of the slightly modified DNA oligonucleotides (ON-1–
A+H2O∙ON-2) remained intact during the HPLC separa-
tion. Only after strand cleavage the retention times were
notably different, indicating the dissociation of the modified
double-stranded DNA into the single-strand ON-2 and the
fragments w5 (ON-1) and d9 (ON-1) of the modified
oligonucleotide ON-1.
In contrast to seco-drug 2, prodrug 1 showed only a very
low reactivity against the dsDNA ON-1∙ON-2 (Fig. 12, for
tables of the masses calculated and found: see Supplemen-
tary Material Tables S10 and S11). In a ratio of 1:1
(Fig. 12a), nearly no alkylation could be detected and even
after 24 h of incubation of the dsDNA with prodrug 1 in a
ratio of 1:5, less than 10% of the DNA had reacted to the
respective covalent adduct (Fig. 12b). During the incuba-
tion with the DNA, no cleavage of the sugar moiety in 1
occurred, so that a direct nucleophilic substitution of the
chlorine atom in prodrug 1 by the DNA took place.
Interestingly, both DNA oligonucleotides were alkylated
to give ON-1* and ON-2* as well as the depurinated
oligonucleotides ON-1-A and ON-2–A, respectively.
Direct ESI–HRMS measurements under harsher condi-
tions (CapExit voltage −150 V) led to an enhanced
fragmentation of the depurinated oligonucleotides to pro-
vide the characteristic fragments A* (Fig. 13a), w5 (ON-1)
and a10–B10 (ON-1) as well as w8(ON-2) and a7–B7 (ON-2)
(Figs. 13b and 14).
Obviously, in the small amount of alkylated dsDNA
obtained by reaction of the dsDNA with an excess of
prodrug 1, reaction had taken place at A-10 of the
oligonucleotide ON-1 and at A-7 of the oligonucleotide
ON-2 (Fig. 14). Thus, prodrug 1 seems to bind in the same
binding mode and orientation to the DNA double-strand as
drug 3, but, owing to the greater flexibility of the alkylating
1-chloroethyl moiety in prodrug 1 in comparison to the
cyclopropyl moiety in 3, alkylation of both strands was
possible (Fig. 15).
Conclusions
The results show that 1 is very suitable as prodrug for the
use in ADEPT since it is not converted into the
corresponding drug 3 in unmodified cell culture medium
on the one hand, but on the other hand it is transformed
efficiently into the seco-drug 2 in the presence of β-D-
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Fig. 15 Depiction of the alkyl-
ation of the oligonucleotides
ON-1 and ON-2 as parts of the
dsDNA ON-1∙ON-2 by the pro-
drug 1 to give the covalent
adducts ON-1* and ON-2*,
respectively
Investigation of the transformations of a novel anti-cancer agent 447galactosidase. 2 cyclises rapidly to give the drug 3 in situ,
which acts as a very potent alkylating agent of double-
stranded DNA, whereas prodrug 1 shows only a very low
alkylation efficiency. Since the alkylation efficiency corre-
lates very well with the cytotoxicity in cell culture
investigations, it is supposed that the drug’s high biological
activity derives from the alkylation of cellular DNA.
The combination of all techniques applied led to a better
understanding of the mode of action of the new com-
pounds. This is a prerequisite for successfully studying the
transformation and metabolism of 1 and its analogues in
living organisms. Furthermore, a novel method for the
direct investigation of the alkylation of DNA by alkylating
agents using ESI–FTICR–MS was developed, which can be
used to estimate relative alkylation efficiencies as well as
the sites of alkylation of the DNA by different alkylating
agents. The latter is based on a characteristic mode of
fragmentation of the modified DNA oligonucleotides in-
duced by CSD or by CID. In addition, mechanisms explain-
ing the different fragmentation of alkylated oligonucleotides
in the mass spectrometer and in solution are provided.
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